|Bid||16.600 x 4200|
|Ask||16.650 x 1800|
|Day's range||16.550 - 16.825|
|52-week range||7.750 - 25.700|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.15|
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
The Hayward, California-based company said it had a loss of 69 cents per share. Earnings, adjusted for one-time gains and costs, were 23 cents per share. The results exceeded Wall Street expectations. ...
The company posted adjusted earnings per share of 22 cents on revenue of $1.4 billion in the third quarter, versus Wall Street expectations of 19 cents and sales of $1.5 billion. In a statement, CEO Kevin Plank said, “While our international business continues to deliver against our ambition of building a global brand, operational challenges and lower demand in North America resulted in third quarter revenue that was below our expectations. Pfizer (PFE) topped earnings expectations in the third quarter and raised its full-year EPS outlook. The pharmaceutical giant reported adjusted earnings per share of 67 cents on revenue of $13.17 billion, its first year-over-year growth in four quarters.
Impax Laboratories Inc. shares rose 4.4% in premarket trade Tuesday after the company said that its generic Renvela, used to lower phosphorus levels for patients on kidney dialysis, had been approved by ...
Impax Laboratories Inc. shares rose in the extended session Monday after the drug maker said the Food and Drug Administration approved its generic version of Sanofi SA's Renvela. Impax shares advanced ...
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
Stocks that moved substantially or traded heavily Tuesday: Morgan Stanley, up 18 cents to $49.12 The company had a better-than-expected third quarter as its wealth management business performed well. Johnson ...
Impax dove after announcing a merger with privately held Amneal to create the fifth-largest generics unit in the U.S.
The Dow (^DJI) pierces 23,000 after strong earnings beats by UnitedHealth (UNH) and Johnson & Johnson (JNJ), but quickly retreats and settles into a low volume trading range for the balance of the day. Plus, Gary Cohn speaks to Yahoo Finance in Washington, D.C. The president’s chief economist tells us what’s open for negotiation and what’s not. Plus, our prophecy for posterity — or as we usually call it, the look ahead — for everything you need to know about tomorrow with your favorite interlocutor. Catch The Final Round at 3:55 p.m. with Jen Rogers and Yahoo Finance’s Myles Udland and Dan Roberts.
The following statement is being issued by Levi & Korsinsky, LLP:
The deal comes at a time when speedy approvals of generics by U.S. regulators have ratcheted up competition in the sector, mounting pressure on smaller drugmakers such as Impax, which has a market cap of about $1.48 billion (£1.1 billion). Adding to the woes of generics makers, U.S. retail pharmacies including Wal-Mart Stores Inc (WMT.N) and Walgreens Boots Alliance Inc (WBA.O) are wielding more leverage when buying such drugs, leading to continued price erosion.
Impax Laboratories Inc. and Amneal Pharmaceuticals LLC have agreed to a merger that would create the nation’s fifth-largest generic-drug company by revenue.
Impax Laboratories Inc. and privately-held Amneal Pharmaceuticals LLC announced Tuesday an agreement to merge in a all-stock deal, forming a new publicly traded company named Amneal Pharmaceuticals Inc. ...
Impax Laboratories Inc. and Amneal Pharmaceuticals LLC are close to agreement on a merger that would create the nation’s fifth-largest generic-drug company by revenue, according to people familiar with ...
BMO Capital Markets' Gary Nachman and his team recently hosted an event with executives from Valeant Pharmaceuticals (VRX), Impax Laboratories (IPXL) and Endo International (ENDP), as they try to navigate a "challenging time in specialty pharma." Nachman writes that all three companies have a high amount of leverage, but they're taking different approaches: While Valeant and Endo are taking a more long-term approach of addressing concerns about their debt by executing their main businesses, Impax appears to be planning a "creative transaction" in the near-term that Nachman writes could "potentially transform the company," while also delevering its balance sheet.